Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CRISPR Therapeutics AG
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.